ENTPD2 and gastric cancer: In this study, the gastric cancer patients with high expression of CTLA4 and ENTPD2 had a better survival prognosis, with high expression of CLDN6, EMB, GPR15, VWF and AKR1B1 suggesting poor prognosis, which was consistent with previous studies.